CLINICAL_TRIALS
trial_result
· 2016-08-26
Clinical Trial Update: A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD) [Phase 3]
Summary
A Phase 3 study of pegylated interferon alfa-2a (Pegasys) in chronic hepatitis D has completed, with results posted in August 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hoffmann-La Roche | Conditions: Hepatitis D, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2016-08-26